CBT Pharmaceuticals to Present at Upcoming Investor Conferences

14-Mar-2018 Intellasia | BusinessWire | 7:00 PM Print This Post

PLEASANTON, Calif.–(BUSINESS WIRE)–CBT Pharmaceuticals (CBT), a U.S. and China-based innovative
biopharmaceutical company committed to becoming a leader in the
discovery and development of oncology combination therapies, today
announced that the company will present at two upcoming investor
conferences:

  • March 23, 2018 – Future Leaders in the Biotech Industry at 2:45 – 3:00
    p.m. EST in New York, N.Y.
  • March 28, 2018 – China Healthcare Investment Conference (CHIC) at 3:15
    – 5:15 p.m. CST in Shanghai, P.R. China

About CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company
committed to becoming a global leader in the discovery and development
of oncology combination therapies by focusing on therapeutics harnessing
the immune system and targeting specific molecular pathways to tame
cancer. The company’s existing pipeline of four development-stage assets
includes two novel humanized monoclonal antibodies – CBT-501, targeting
the Programmed Death-1 (PD-1) membrane receptor of immune cells, as well
as Programmed Death Ligand-1 (PD-L1) (CBT-502) that restores the body’s
immune system to recognize and kill cancer cells. In addition, CBT-101,
is an oral c-MET inhibitor targeting the epithelial to mesenchymal
transition (EMT) pathway and CBT-102, an oral multi-targeted kinase
inhibitor that targets uncontrolled growth signaling pathways. The
company was founded in 2016. For more information, please visit www.cbtpharma.com
and follow us on [email protected]

Contacts

MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
[email protected]

 


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.